<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>From 1963 to 1988, 281 patients suffering follicular <z:hpo ids='HP_0002665'>lymphomas</z:hpo> and without previous treatment were treated in the same institution </plain></SENT>
<SENT sid="1" pm="."><plain>One hundred and thirty three had a <z:e sem="disease" ids="C0277565" disease_type="Disease or Syndrome" abbrv="">localized disease</z:e> (72 stages I, 61 stages II) ans 148 an extended disease (83 stages III and 85 stages IV) </plain></SENT>
<SENT sid="2" pm="."><plain>In the absence of dramatic therapeutic improvement quite <z:hpo ids='HP_0000001'>all</z:hpo> patients were treated in a homogeneous manner with radical radiotherapy for <z:e sem="disease" ids="C0277565" disease_type="Disease or Syndrome" abbrv="">localized disease</z:e> and palliative chemotherapy for extended ones </plain></SENT>
<SENT sid="3" pm="."><plain>Median follow-up is 9 years </plain></SENT>
<SENT sid="4" pm="."><plain>Ten year overall survival is 38% and relapse free survival 29.5% </plain></SENT>
<SENT sid="5" pm="."><plain>Multivariate analysis show two main prognosis factors: age (+ or - 60 years) and tumoral mass (as shown by stage or number of involved area) </plain></SENT>
<SENT sid="6" pm="."><plain>Survival depends also on complete remission </plain></SENT>
<SENT sid="7" pm="."><plain>Age and tumoral mass allows us to define three prognosis groups: favorable, intermediate, unfavorable </plain></SENT>
<SENT sid="8" pm="."><plain>These groups justify different therapeutic approach and different proposals for prospective therapeutic trials </plain></SENT>
</text></document>